Medivis
-50%
est. 2Y upside i
Medivis uses technological advancements in augmented reality and computer vision to create a holographic future for surgery.
Rank
#524
Sector
HealthTech
Est. Liquidity
~4Y
Data Quality
Data: MediumMedivis presents a moderate upside opportunity for a job seeker, with an estimated current valuation of $100M and annual revenue of $11M.
Last updated: March 10, 2026
Medivis's Cranial Navigation platform, with its recent FDA clearance, achieves rapid adoption in neurosurgery, and the company secures a major partnership with a large medical device distributor, accelerating market penetration. Revenue exceeds $75M by 2028, leading to an acquisition at a 6-7x revenue multiple, valuing the company at $450M-$525M.
Medivis continues to grow steadily, leveraging its FDA clearances for Spine and Cranial Navigation and its strong competitive moat. It expands its customer base among leading medical centers but faces ongoing competition from well-funded players like Augmedics and Proximie. Revenue reaches $35M-$40M by 2028, leading to a Series B or C round at a valuation of $175M-$200M.
Despite FDA clearances, market adoption is slower than expected due to high capital intensity and the competitive landscape, including a patent litigation loss to Novarad. A larger incumbent or well-funded competitor gains significant market share. Medivis struggles to raise its next round at an up-valuation, leading to a flat or down round, or a distressed acquisition, resulting in a valuation of $25M-$30M, significantly impacting common stock value due to liquidation preferences.
Preference Stack Risk
highInvestors hold $25M in liquidation preferences ahead of common stock. In an exit at or below the estimated $100M valuation, common shareholders would receive significantly less, or potentially nothing in a distressed scenario.
Dilution Risk
highAs a Series A company, Medivis will almost certainly require additional significant funding rounds (Series B, Series C) before a liquidity event, which will dilute existing equity holders.
Secondary Liquidity
noneThere is currently no active secondary market or tender offers for Medivis shares, which is typical for a company at this stage.
Questions to Ask at the Interview
Strategic questions based on Medivis's data — designed to show you've done your homework.
- 1
“Given the recent FDA clearance for your Cranial Navigation platform and the existing Spine Navigation, how is Medivis prioritizing its go-to-market strategy across these specialties, especially considering the competitive landscape with players like Augmedics and Proximie?”
- 2
“Medivis has secured partnerships with notable institutions like MD Anderson and Northwell Health. What is the long-term strategy for scaling customer acquisition beyond these flagship partnerships, and how does the revenue model support this expansion?”
- 3
“As a Series A company with high capital intensity, what is the company's outlook on future funding rounds and potential liquidity events within a 2-4 year horizon, and how might that impact employee equity?”
Community
Valuation Sentiment
Our model estimates -50% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.